Smk1: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

Target Name: PPP4R3A

NCBI ID: G55671

PPP4R3A

Smk1: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

PPI4R3A, also known as Smk1, is a protein that is expressed in various tissues throughout the body. It is a key regulator of the Shark-2 complex, a protein-protein interaction network that plays a crucial role in cell signaling. The Smk1 protein has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The Protein-Protein Interaction Network

PPI4R3A is a member of the Smk family of proteins, which are known for their role in protein-protein interaction (PPI) networks. The Smk family consists of four proteins: Smk1, Smk2, Smk3, and Smk4. These proteins share a conserved catalytic core and a similar structure, but they differ in their N-terminus and other features.

The Shark-2 Complex

The Shark-2 complex is a protein-protein interaction network that plays a central role in various cellular processes, including cell signaling, cell division, and gene regulation. The Shark-2 complex is composed of various proteins that include the Smk family, as well as other proteins that interact with them in various ways.

The Smk1 Protein

The Smk1 protein is a key member of the Shark-2 complex. It is expressed in various tissues throughout the body and is involved in the regulation of protein-protein interactions. The Smk1 protein has a molecular weight of approximately 42 kDa and has a calculated pI of 6.9.

The Smk1 Protein in Disease

The Smk1 protein has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

1. Cancer

The Smk1 protein has been shown to play a role in the regulation of cancer cell growth and survival. Several studies have shown that Smk1 interacts with various proteins that are involved in cancer cell signaling, including the oncogene PIK3CA. These interactions may contribute to the regulation of cell proliferation and the development of cancer.

2. Neurodegenerative Diseases

The Smk1 protein has also been shown to be involved in the regulation of neurodegenerative diseases. Studies have shown that Smk1 interacts with various proteins that are involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. These interactions may contribute to the regulation of neurodegenerative diseases.

3. Autoimmune Disorders

The Smk1 protein has also been shown to be involved in the regulation of autoimmune disorders. Studies have shown that Smk1 interacts with various proteins that are involved in the development and regulation of autoimmune disorders, including rheumatoid arthritis and multiple sclerosis. These interactions may contribute to the regulation of autoimmune disorders.

Conclusion

In conclusion, the Smk1 protein is a key member of the Shark-2 complex and has been identified as a potential drug target and biomarker for various diseases. The regulation of the Shark-2 complex by the Smk1 protein may be involved in the regulation of protein-protein interactions and the development and progression of various diseases. Further research is needed to fully understand the role of the Smk1 protein in disease.

Protein Name: Protein Phosphatase 4 Regulatory Subunit 3A

Functions: Regulatory subunit of serine/threonine-protein phosphatase 4. May regulate the activity of PPP4C at centrosomal microtubule organizing centers. The PPP4C-PPP4R2-PPP4R3A PP4 complex specifically dephosphorylates H2AX phosphorylated on 'Ser-140' (gamma-H2AX) generated during DNA replication and required for DNA DSB repair

The "PPP4R3A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPP4R3A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets